AU2021253866A1 - Methods of treating SARS-CoV-2 infections - Google Patents

Methods of treating SARS-CoV-2 infections Download PDF

Info

Publication number
AU2021253866A1
AU2021253866A1 AU2021253866A AU2021253866A AU2021253866A1 AU 2021253866 A1 AU2021253866 A1 AU 2021253866A1 AU 2021253866 A AU2021253866 A AU 2021253866A AU 2021253866 A AU2021253866 A AU 2021253866A AU 2021253866 A1 AU2021253866 A1 AU 2021253866A1
Authority
AU
Australia
Prior art keywords
dantrolene
administering
subject
host cell
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021253866A
Other languages
English (en)
Inventor
Adrian HEPNER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eagle Pharmaceuticals Inc
Original Assignee
Eagle Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eagle Pharmaceuticals Inc filed Critical Eagle Pharmaceuticals Inc
Publication of AU2021253866A1 publication Critical patent/AU2021253866A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2021253866A 2020-04-10 2021-04-08 Methods of treating SARS-CoV-2 infections Pending AU2021253866A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063008486P 2020-04-10 2020-04-10
US63/008,486 2020-04-10
US202063062599P 2020-08-07 2020-08-07
US63/062,599 2020-08-07
PCT/US2021/026302 WO2021207443A1 (en) 2020-04-10 2021-04-08 Methods of treating sars-cov-2 infections

Publications (1)

Publication Number Publication Date
AU2021253866A1 true AU2021253866A1 (en) 2022-10-20

Family

ID=75787221

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021253866A Pending AU2021253866A1 (en) 2020-04-10 2021-04-08 Methods of treating SARS-CoV-2 infections

Country Status (12)

Country Link
US (1) US12605364B2 (https=)
EP (1) EP4132518B1 (https=)
JP (1) JP2023521163A (https=)
KR (1) KR20230002371A (https=)
CN (1) CN115361947A (https=)
AU (1) AU2021253866A1 (https=)
BR (1) BR112022020193A2 (https=)
CA (1) CA3174710A1 (https=)
IL (1) IL296517A (https=)
MX (1) MX2022012705A (https=)
WO (1) WO2021207443A1 (https=)
ZA (1) ZA202210474B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021254415A1 (en) * 2020-04-10 2022-10-20 Eagle Pharmaceuticals, Inc. Methods of treating Severe Acute Respiratory Syndrome

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY201417A (en) * 2017-10-20 2024-02-21 Eagle Res Labs Limited Dantrolene prodrugs and methods of their use
US11123328B2 (en) 2017-11-14 2021-09-21 University Health Network Dantrolene and analogs thereof for the chronic treatment and prevention of dyssynchronous cardiac dysfunction
WO2019175761A1 (en) 2018-03-12 2019-09-19 Orbicular Pharmaceutical Technologies Private Limited Ready to use dantrolene compositions
US12246028B2 (en) * 2018-11-27 2025-03-11 Eagle Research Labs Limited Use of dantrolene and dantrolene prodrugs to treat radiation exposure
AU2021254415A1 (en) * 2020-04-10 2022-10-20 Eagle Pharmaceuticals, Inc. Methods of treating Severe Acute Respiratory Syndrome

Also Published As

Publication number Publication date
CN115361947A (zh) 2022-11-18
KR20230002371A (ko) 2023-01-05
US20230144719A1 (en) 2023-05-11
ZA202210474B (en) 2025-12-17
MX2022012705A (es) 2022-11-07
WO2021207443A1 (en) 2021-10-14
JP2023521163A (ja) 2023-05-23
EP4132518A1 (en) 2023-02-15
IL296517A (en) 2022-11-01
US12605364B2 (en) 2026-04-21
EP4132518C0 (en) 2025-08-13
CA3174710A1 (en) 2021-10-14
BR112022020193A2 (pt) 2022-11-22
EP4132518B1 (en) 2025-08-13

Similar Documents

Publication Publication Date Title
WO2021155777A1 (zh) 药物组合物在预防和治疗新型冠状病毒肺炎中的应用
Alfano et al. Awaiting a cure for COVID-19: therapeutic approach in patients with different severity levels of COVID-19
US12605364B2 (en) Methods of treating SARS-CoV-2 infections
US12582633B2 (en) Methods of treating severe acute respiratory syndrome
US20230181509A1 (en) The use of diffusion enhancing compounds for treatment of viral and bacterial induced respiratory disease
HK40083259B (en) Dantrolene for use in methods of treating sars-cov-2 infections
HK40083259A (en) Dantrolene for use in methods of treating sars-cov-2 infections
EP4132519A1 (en) Methods of treating coronavirus infections
Qasem et al. Varicella pneumonia in immunocompetent adults: symptomatic and asymptomatic cases
WO2021207446A1 (en) Methods of treating viral infections
KR20210129579A (ko) 사스 코로나바이러스 감염증 치료용 약학적 조성물
HK40090314A (zh) 治疗严重急性呼吸综合征的方法
US20250281576A1 (en) Prophylactic administration method against respiratory virus, comprising administering interferon-beta to potential respiratory virus-infected subject
KR20220009314A (ko) 사스-코로나바이러스-2 감염증 예방 또는 치료용 약학 조성물
Aoki Peramivir
Novozhilova et al. Oral health in patients with COVID-19: a literature review
Jeffrey Miskoff Novel coronavirus 2019 (COVID-19)
TW202102224A (zh) 使用經取代之多環吡啶酮衍生物及其前藥於患有流感及嚴重流感病況之個體中治療流感
IT202300022647A1 (it) Uso di elysivir per il trattamento della malattia da coronavirus 2019 (covid-19)
Alfano et al. Le Infezioni in Medicina, n. 1, 11-21, 2022
EA048350B1 (ru) Применение даларгина для профилактики орви и предотвращения развития осложнений при заболеваниях орви